论文部分内容阅读
目的:评价国产新福菌素对老年非小细胞肺癌(NSCLC)的疗效和不良反应。方法:选取老年NSCLC病例81例,随机分治疗组43例给予新福菌素6μg/kg(第1~4d),卡铂(CBP)300mg/m2(第1d),依托泊苷(VP-16)100mg(第1~4或5d)静脉滴注;对照组38例单纯使用CBP和VP-16,剂量和方法同治疗组,21~28d为一个疗程,2~3个疗程评价疗效,随访缓解期和生存期。结果:治疗组有效率为53·49%,对照组有效率为31·58%,差异有显著性(P<0·05);中位缓解期分别为6和4·5个月,中位生存期分别为9和7个月,一年生存率分别为39·53%(17/43)和26·32%(10/38)。结论:新福菌素联合CBP、VP-16治疗老年NSCLC有较好的临床疗效及应用价值。
Objective: To evaluate the curative effect and adverse reactions of domestic-made nefactin on elderly non-small cell lung cancer (NSCLC). Methods: A total of 81 elderly patients with NSCLC were enrolled in this study. Forty-three NSCLC patients were randomly assigned to receive either 4μg / kg of streptozotocin (1st to 4th day), 300mg / m2 of CBP (1st day), etoposide ) 100mg (1 ~ 4 or 5d) intravenous drip; the control group 38 cases of pure use of CBP and VP-16, the same dose and method of treatment group, 21 ~ 28d for a course of treatment, 2 ~ 3 courses evaluation of efficacy, Period and survival. Results: The effective rate was 53.49% in the treatment group and 31.58% in the control group, with a significant difference (P <0.05). The median remission rates were 6 and 4.5 months respectively. The median The survival rates were 9 and 7 months respectively. The one-year survival rates were 39.53% (17/43) and 26.32% (10/38), respectively. Conclusion: The combination of neomycin with CBP and VP-16 in the treatment of elderly NSCLC has good clinical curative effect and application value.